Friday, August 7, 2020
Cocrystal Pharma Inc. (COCP)
Q2 EPS: Transformational 12 Months Ahead
Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Q2 2020 financial results. The company reported $19.4 million cash balance as of June 30, 2020. Net operating loss was $4.0 million for the quarter with $2.0 million research and development expenses and $2.0 million general and administrative expenses. Cocrystal reported ($0.07) EPS.
Maintaining our F2020 estimates. We think the reported numbers are in line with our F2020 estimates. We are forecasting $5.6 of R&D expenses and $5.0 million of SG&A expenses. Our F2020 estimates are …
Click to get the full report.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.